Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (INSPIRE)

This study has been terminated.
(The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.)
Information provided by (Responsible Party):
Merck KGaA Identifier:
First received: October 1, 2009
Last updated: September 3, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):